Lilly/Alkermes Broaden Inhaled Insulin Manufacturing Agreement
This article was originally published in The Pink Sheet Daily
Executive Summary
The update ensures adequate supplies of insulin powder “if and when” the AIR inhaled insulin system is launched, Lilly told “The Pink Sheet” DAILY.
You may also be interested in...
Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade
Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.
Five Late-Stage Products In Lilly’s Pipeline Could Launch By End Of Decade
Mid- and late-stage pipeline opportunities, including gamma secretase inhibitor for Alzheimer’s and long-acting versions of Byetta and Zyprexa, fuel Lilly’s optimism.
Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts
Driven by rising obesity rates, spending on diabetes therapies rose 14.5 percent from 2005 to 2006, firm’s annual Drug Trend Report states.